Larger, longer, and randomized trials are required to adequately test this above hypothesis. Conclusions: On the basis of the results of this meta-analysis TAVR may be a safe and effective therapeutic option for patients with cancer and symptomatic severe aortic stenosis. Meta-regression demonstrated there was no significant association modifying. The rates of bleeding and need for new pacemaker implantation were not significantly different. The frequency of AKI was 14.2% in cancer patients vs. The frequency of stroke was 2.4% compared with 2.7% (odds ratio of 0.87, 95% confidence interval: 0.76-0.99 p < 0.04). The short-term mortality in the cancer group was 2.4% compared with 3.3% in the control group (odds ratio: 0.72, 95% confidence interval: 0.63-0.82 p < 0.0001). Results: Five studies with 11,129 patients in the cancer group and 41,706 patients in the control group met inclusion criteria. Meta-regression was also conducted to determine if common clinical factors modified the possible association between cancer status and TAVR mortality.
![meta comprehensive meta analysis meta comprehensive meta analysis](https://i.ytimg.com/vi/XGuY_rb_fpM/maxresdefault.jpg)
Studies that compared the use of TAVR in patients with severe symptomatic aortic stenosis and cancer against patients without cancer were included. Methods: We performed a literature search using PubMed, EMBASE, and Cochrane Central Register of Controlled Trials from January 2015 to 2020. We thus conducted the largest known multi-center meta-analysis on TAVR and cancer status. The safety and efficacy of TAVR in cancer patients has not yet been reliably established. TAVR has expanded the treatment options for this lethal disease process. Background: Aortic stenosis is the most common valvular heart disease in the world.
![meta comprehensive meta analysis meta comprehensive meta analysis](https://www.researchgate.net/publication/325048646/figure/fig7/AS:624430669631490@1525887281569/Forest-plot-of-subgroup-analysis-for-the-integrated-meta-analysis-Subgroup-analysis-was.png)
Objectives: This study sought to systematically analyze the available clinical evidence on TAVR therapy in cancer patients with symptomatic severe AS.